Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.
20hon MSN
Q4 2024 Management View CEO Ryan Spencer highlighted the company’s record HEPLISAV-B product revenue in Q4 and 2024, achieving profitability and implementing a share repurchase plan. Looking ahead, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback